Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRP in maxillary bony defects
NCT07108933Phase 2Completed
- Sponsor
- Horus Pharma
- Start
- Aug 2023
- Primary completion
- Oct 2024
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous platelet-rich plasma in maxillary bone defect, sponsored by Horus Pharma. Primary endpoint: Volume of the injected bony defect at 3 months. Started Aug 2023; status: completed.
02
Drugs
autologous platelet-rich plasma
03
Conditions
maxillary bone defect
Beyond the preview
Go deeper on NCT07108933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07108933.